27 research outputs found
Gut microbes in the prevention and onset of metabolic disorders
ABSTRACT:
Gut microbes are suggested to play an essential role in maintaining humanhealth, and unfavorable alterations in gut microbiota have been associated with several human diseases and disorders. Despite the significant advancements in analysis tools, several sources of uncertainty still exist in the gut microbiota composition analyses, limiting the reproducibility and comparability of the results from distinct gut microbiota studies.
The first main aim of this study was to set up a functional high-throughput pipeline for 16S rRNA gene sequencing -based gut microbiota composition analysis. This was achieved by evaluating the effects of fecal sample processing, i.e. two sample storage conditions and five DNA extraction kits, along with two different 16S rRNA gene sequencing protocols. The second main aim of this study was to explore the role of gut microbiota in the onset of obesity-related metabolic disorders such as non-alcoholic fatty liver disease. This was done by studying the effects of intragastric administration of two distinct gut microbes, Faecalibacterium prausnitzii and Enterobacter cloacae, on host health and metabolism of high fat diet -fed C57BL/6N mice.
The results of this study showed that the 16S rRNA gene sequencing protocol had a significant effect on the analysis results. Meanwhile, the effect of sample pre-processing was more modest, yet still potentially important. These results indicate that careful design and adequate method optimization are required in order to produce reliable 16S rRNA gene sequencing results. Moreover, the results of this study revealed that the intragastric F. prausnitzii administration appeared to protect the C57BL/6N mice from liver steatosis, whereas the intragastric administration of E. cloacae seemed to induce liver damage. Further studies are needed in order to clarify the underlying mechanisms and to fully
elucidate the possible therapeutic potential of F. prausnitzii.TIIVISTELMĂ„:
Suolistobakteereilla uskotaan olevan merkittävä vaikutus ihmisen terveydelle, ja suolistomikrobiston epätasapaino on yhdistetty moniin eri sairauksiin ja oireyhtymiin. Mikrobistotutkimuksessa käytettävät analyysimenetelmät ovat viimeisen vuosikymmenen aikana kehittyneet merkittävästi, mutta analyysitulokset ovat yhä vahvasti menetelmäriippuvaisia, mikä heikentää tutkimusten toistettavuutta sekä tulosten luotettavuutta ja vertailukelpoisuutta.
Tämän tutkimuksen ensimmäisenä päätavoitteena oli pystyttää toimivat menetelmät 16S rRNA -geenisekvensointiin perustuvalle mikrobistoanalytiikalle. Tutkimuksessa vertailtiin viittä eri DNA-eristysmenetelmää sekä kahta eri sekvensointiprotokollaa, ja selvitettiin ulostenäytteiden pakastuksen vaikutusta mikrobistoanalyysin tuloksiin. Tutkimuksen toisena päätavoitteena oli kartoittaa hiirimallin avulla suolistomikrobiston roolia ei-alkoholiperäisen rasvamaksan synnyssä. Tutkimuksessa selvitettiin, miten suun kautta tapahtuva Faecalibacterium prausnitzii- tai Enterobacter cloacae -annostelu vaikutti korkearasvaista ravintoa syövien C57BL/6N-hiirten terveyteen jaaineenvaihduntaan.
Tutkimuksen tulokset osoittivat, että 16S rRNA –geenisekvensointimenetelmällä oli merkittävä vaikutus mikrobistoanalyysista saataviin tuloksiin. Näytteiden esikäsittelyn vaikutus oli huomattavasti vähäisempi, mutta kuitenkin tulosten vertailukelpoisuuden kannalta mahdollisesti merkityksellinen. Tulokset osoittavat, että huolellinen suunnittelu ja asianmukainen menetelmäoptimointi ovat välttämättömiä luotettavien 16S rRNA –geenisekvensointituloksen tuottamiseksi. Lisäksi tämän tutkimuksen tulokset osoittivat, että F. prausnitzii -annostelu vaikutti positiivisesti hiirten aineenvaihduntaan ja vähensi hiirten maksan rasvoittumista, kun taas E. cloacae -annostelu aiheutti maksavaurioita. F prausnitzii -suolistobakteerin mahdollista terveyttä edistävää potentiaalia ja taustalla olevia tekijöitä tulisi selvittää tarkemmissa jatkotutkimuksissa
IRF2BP2 Mutation Is Associated with Increased STAT1 and STAT5 Activation in Two Family Members with Inflammatory Conditions and Lymphopenia
Interferon regulatory factor 2 binding protein 2 (IRF2BP2) is a transcriptional coregulator that has an important role in the regulation of the immune response. IRF2BP2 has been associated with the Janus kinase (JAK)—signal transducers and activators of transcription (STAT) pathway, but its exact role remains elusive. Here, we identified a novel clinical variant, IRF2BP2 c.625_665del, from two members of a family with inflammatory conditions and investigated the function of IRF2BP2 and c.625_665del mutation in JAK–STAT pathway activation and inflammatory signaling. The levels of constitutive and cytokine-induced phosphorylation of STATs and total STAT1 in peripheral blood monocytes, T cells, and B cells from the patients and four healthy controls were measured by flow cytometry. Inflammation-related gene expression was studied in peripheral blood mononuclear cells using direct digital detection of mRNA (NanoString). Finally, we studied the relationship between IRF2BP2 and STAT1 activation using a luciferase reporter system in a cell model. Our results show that patients having the IRF2BP2 c.625_665del mutation presented overexpression of STAT1 protein and increased constitutive activation of STAT1. In addition, interferon-induced JAK–STAT signaling was upregulated, and several interferon-inducible genes were overexpressed. Constitutive phosphorylation of STAT5 was also found to be upregulated in CD4+ T cells from the patients. Using a cell model, we show that IRF2BP2 was needed to attenuate STAT1 transcriptional activity and that IRF2BP2 c.625_665del mutation failed in this. We conclude that IRF2BP2 has an important role in suppressing immune responses elicited by STAT1 and STAT5 and suggest that aberrations in IRF2BP2 can lead to abnormal function of intrinsic immunity
IRF2BP2 Mutation Is Associated with Increased STAT1 and STAT5 Activation in Two Family Members with Inflammatory Conditions and Lymphopenia
Interferon regulatory factor 2 binding protein 2 (IRF2BP2) is a transcriptional coregulator that has an important role in the regulation of the immune response. IRF2BP2 has been associated with the Janus kinase (JAK)—signal transducers and activators of transcription (STAT) pathway, but its exact role remains elusive. Here, we identified a novel clinical variant, IRF2BP2 c.625_665del, from two members of a family with inflammatory conditions and investigated the function of IRF2BP2 and c.625_665del mutation in JAK–STAT pathway activation and inflammatory signaling. The levels of constitutive and cytokine-induced phosphorylation of STATs and total STAT1 in peripheral blood monocytes, T cells, and B cells from the patients and four healthy controls were measured by flow cytometry. Inflammation-related gene expression was studied in peripheral blood mononuclear cells using direct digital detection of mRNA (NanoString). Finally, we studied the relationship between IRF2BP2 and STAT1 activation using a luciferase reporter system in a cell model. Our results show that patients having the IRF2BP2 c.625_665del mutation presented overexpression of STAT1 protein and increased constitutive activation of STAT1. In addition, interferon-induced JAK–STAT signaling was upregulated, and several interferon-inducible genes were overexpressed. Constitutive phosphorylation of STAT5 was also found to be upregulated in CD4+ T cells from the patients. Using a cell model, we show that IRF2BP2 was needed to attenuate STAT1 transcriptional activity and that IRF2BP2 c.625_665del mutation failed in this. We conclude that IRF2BP2 has an important role in suppressing immune responses elicited by STAT1 and STAT5 and suggest that aberrations in IRF2BP2 can lead to abnormal function of intrinsic immunity
Blocking Activin Receptor Ligands Is Not Sufficient to Rescue Cancer-Associated Gut Microbiota—A Role for Gut Microbial Flagellin in Colorectal Cancer and Cachexia?
Colorectal cancer (CRC) and cachexia are associated with the gut microbiota and microbial surface molecules. We characterized the CRC-associated microbiota and investigated whether cachexia affects the microbiota composition. Further, we examined the possible relationship between the microbial surface molecule flagellin and CRC. CRC cells (C26) were inoculated into mice. Activin receptor (ACVR) ligands were blocked, either before tumor formation or before and after, to increase muscle mass and prevent muscle loss. The effects of flagellin on C26-cells were studied in vitro. The occurrence of similar phenomena were studied in murine and human tumors. Cancer modulated the gut microbiota without consistent effects of blocking the ACVR ligands. However, continued treatment for muscle loss modified the association between microbiota and weight loss. Several abundant microbial taxa in cancer were flagellated. Exposure of C26-cells to flagellin increased IL6 and CCL2/MCP-1 mRNA and IL6 excretion. Murine C26 tumors expressed more IL6 and CCL2/MCP-1 mRNA than C26-cells, and human CRC tumors expressed more CCL2/MCP-1 than healthy colon sites. Additionally, flagellin decreased caspase-1 activity and the production of reactive oxygen species, and increased cytotoxicity in C26-cells. Conditioned media from flagellin-treated C26-cells deteriorated C2C12-myotubes and decreased their number. In conclusion, cancer increased flagellated microbes that may promote CRC survival and cachexia by inducing inflammatory proteins such as MCP-1. Cancer-associated gut microbiota could not be rescued by blocking ACVR ligands
Blocking Activin Receptor Ligands Is Not Sufficient to Rescue Cancer-Associated Gut Microbiota—A Role for Gut Microbial Flagellin in Colorectal Cancer and Cachexia?
Colorectal cancer (CRC) and cachexia are associated with the gut microbiota and microbial surface molecules. We characterized the CRC-associated microbiota and investigated whether cachexia affects the microbiota composition. Further, we examined the possible relationship between the microbial surface molecule flagellin and CRC. CRC cells (C26) were inoculated into mice. Activin receptor (ACVR) ligands were blocked, either before tumor formation or before and after, to increase muscle mass and prevent muscle loss. The effects of flagellin on C26-cells were studied in vitro. The occurrence of similar phenomena were studied in murine and human tumors. Cancer modulated the gut microbiota without consistent effects of blocking the ACVR ligands. However, continued treatment for muscle loss modified the association between microbiota and weight loss. Several abundant microbial taxa in cancer were flagellated. Exposure of C26-cells to flagellin increased IL6 and CCL2/MCP-1 mRNA and IL6 excretion. Murine C26 tumors expressed more IL6 and CCL2/MCP-1 mRNA than C26-cells, and human CRC tumors expressed more CCL2/MCP-1 than healthy colon sites. Additionally, flagellin decreased caspase-1 activity and the production of reactive oxygen species, and increased cytotoxicity in C26-cells. Conditioned media from flagellin-treated C26-cells deteriorated C2C12-myotubes and decreased their number. In conclusion, cancer increased flagellated microbes that may promote CRC survival and cachexia by inducing inflammatory proteins such as MCP-1. Cancer-associated gut microbiota could not be rescued by blocking ACVR ligands
Six-Week Endurance Exercise Alters Gut Metagenome That Is not Reflected in Systemic Metabolism in Over-weight Women
Recent studies suggest that exercise alters the gut microbiome. We determined whether six-weeks endurance exercise, without changing diet, affected the gut metagenome and systemic metabolites of overweight women. Previously sedentary overweight women (n = 19) underwent a six-weeks endurance exercise intervention, but two were excluded due to antibiotic therapy. The gut microbiota composition and functions were analyzed by 16S rRNA gene amplicon sequencing and metagenomics. Body composition was analyzed with DXA X-ray densitometer and serum metabolomics with NMR metabolomics. Total energy and energy-yielding nutrient intakes were analyzed from food records using Micro-Nutrica software. Serum clinical variables were determined with KONELAB instrument. Soluble Vascular Adhesion Protein 1 (VAP-1) was measured with ELISA and its' enzymatic activity as produced hydrogen peroxide. The exercise intervention was effective, as maximal power and maximum rate of oxygen consumption increased while android fat mass decreased. No changes in diet were observed. Metagenomic analysis revealed taxonomic shifts including an increase in Akkermansia and a decrease in Proteobacteria. These changes were independent of age, weight, fat % as well as energy and fiber intake. Training slightly increased Jaccard distance of genus level β-diversity. Training did not alter the enriched metagenomic pathways, which, according to Bray Curtis dissimilarity analysis, may have been due to that only half of the subjects' microbiomes responded considerably to exercise. Nevertheless, tranining decreased the abundance of several genes including those related to fructose and amino acid metabolism. These metagenomic changes, however, were not translated into major systemic metabolic changes as only two metabolites, phospholipids and cholesterol in large VLDL particles, decreased after exercise. Training also decreased the amine oxidase activity of pro-inflammatory VAP-1, whereas no changes in CRP were detected. All clinical blood variables were within normal range, yet exercise slightly increased glucose and decreased LDL and HDL. In conclusion, exercise training modified the gut microbiome without greatly affecting systemic metabolites or body composition. Based on our data and existing literature, we propose that especially Akkermansia and Proteobacteria are exercise-responsive taxa. Our results warrant the need for further studies in larger cohorts to determine whether exercise types other than endurance exercise also modify the gut metagenome
Gut microbiota composition is associated with temperament traits in infants
Background: One of the key behavioral phenotypes in infancy are different temperament traits, and certain early life temperament traits have been shown to precede later mental health problems. Differences in the gut microbiota composition (GMC) have been suggested to link with neurodevelopment. For example, toddler temperament traits have been found to associate with differences in GMC; however, studies in infants are lacking although infancy is a rapid period of neurodevelopment as well as GM development. Thus, we aimed to investigate association between infant GMC and temperament. Methods: The study population (n = 301, 53% boys) was drawn from the FinnBrain Birth Cohort Study. Stool samples were collected from the 2.5-month-old infants and sequenced with 16S Illumina MiSeq platform. GMC taxonomic composition (at Genus and OTU level), observed sample clusters, diversity and richness were investigated in relation to the maternal reports of Infant Behavior Questionnaire -Revised (IBQ-R) at the age of 6 months. Results: Three sample clusters (Bifidobacterium/Enterobacteriaceae, Bacteroides, V. Dispar) based on GMC were identified, of which Bifidobacterium/Enterobacteriaceae–cluster presented with higher scores on the IBQ-R main dimension regulation and its subscale duration of orienting compared to Bacteroides-cluster. The clusters associated with temperament in a sex-dependent manner. The IBQ-R main dimension surgency (positive emotionality) was associated positively both with genus Bifidobacterium and Streptococcus. Alpha diversity had a negative association with negative emotionality and fear reactivity. Conclusion This is the first study demonstrating associations, but not causal connections, between GMC and temperament in young infants in a prospective design
Chlamydia trachomatis samples testing falsely negative in the Aptima Combo 2 test in Finland, 2019
Since February 2019, over 160 Chlamydia trachomatis (CT) cases testing negative or equivocal by Aptima Combo 2 (AC2) but positive by Aptima CT test run with Panther instruments occurred in Finland. The AC2 test targets chlamydial 23S rRNA while the CT test targets 16S rRNA. Sequencing of 10 strains revealed a nucleotide substitution in 23S rRNA. The significance of this for the failure of the AC2 test to detect the variant is not yet known.Peer reviewe
Blocking activin receptor ligands is not sufficient to rescue cancer-associated gut microbiota - a role for gut microbial flagellin in colorectal cancer and cachexia?
Colorectal cancer (CRC) and cachexia are associated with the gut
microbiota and microbial surface molecules. We characterized the
CRC-associated microbiota and investigated whether cachexia affects the
microbiota composition. Further, we examined the possible relationship
between the microbial surface molecule flagellin and CRC. CRC cells
(C26) were inoculated into mice. Activin receptor (ACVR) ligands were
blocked, either before tumor formation or before and after, to increase
muscle mass and prevent muscle loss. The effects of flagellin on
C26-cells were studied in vitro. The occurrence of similar phenomena
were studied in murine and human tumors. Cancer modulated the gut
microbiota without consistent effects of blocking the ACVR ligands.
However, continued treatment for muscle loss modified the association
between microbiota and weight loss. Several abundant microbial taxa in
cancer were flagellated. Exposure of C26-cells to flagellin increased IL6 and CCL2/MCP-1 mRNA and IL6 excretion. Murine C26 tumors expressed more IL6 and CCL2/MCP-1
mRNA than C26-cells, and human CRC tumors expressed more CCL2/MCP-1
than healthy colon sites. Additionally, flagellin decreased caspase-1
activity and the production of reactive oxygen species, and increased
cytotoxicity in C26-cells. Conditioned media from flagellin-treated
C26-cells deteriorated C2C12-myotubes and decreased their number. In
conclusion, cancer increased flagellated microbes that may promote CRC
survival and cachexia by inducing inflammatory proteins such as MCP-1.
Cancer-associated gut microbiota could not be rescued by blocking ACVR
ligands.</p